Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Barei

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
The Journal of Dermatological Treatment|October 13, 2024
Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictorsFrancesca Barei, Paolo Calzari, Luca Valtellini, et al.
International Journal of Dermatology|October 17, 2025
Phenotypic Switch From Atopic Dermatitis to Psoriasis During Dupilumab Therapy: A Real-Life Experience From a Tertiary Referral CenterAlessandra Chiei Gallo, Gianluca Tavoletti, Davide Termini, et al.
The Journal of Dermatology|August 17, 2022
Five cases of new-onset pemphigus following vaccinations against coronavirus disease 2019Alberto Corrá, Francesca Barei, Giovanni Genovese, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 28, 2024
Effectiveness of dupilumab in tralokinumab-resistant patients with atopic dermatitis: A real-world experience from two referral centresGianluca Tavoletti, Alessandra Chiei-Gallo, Luigi Gargiulo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 27, 2022
Clinical spectrum of human monkeypox: An Italian single-centre case seriesItalo F Aromolo, Carlo A Maronese, Gianluca Avallone, et al.
Journal of the American Academy of Dermatology|July 24, 2024
Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series studyElena Pezzolo, Alessandra Narcisi, Luigi Gargiulo, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|July 31, 2025
Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort StudyGianluca Avallone, Luca Valtellini, Gianluca Tavoletti, et al.
Journal of Clinical Medicine|January 23, 2024
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter AnalysisElena Pezzolo, Michela Ortoncelli, Silvia Mariel Ferrucci, et al.
Archives of Dermatological Research|May 23, 2025
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis)Luca Potestio, Cataldo Patruno, Alessandra Narcisi, et al.
Clinical and Experimental Dermatology|February 3, 2025
Efficacy and Drug Survival of Tralokinumab in Severe Atopic Dermatitis: An 18-Month Multicenter ExperienceFrancesca Barei, Paolo Calzari, Elena Pezzolo, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
The Journal of Dermatological Treatment|October 13, 2024
Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictorsFrancesca Barei, Paolo Calzari, Luca Valtellini, et al.
International Journal of Dermatology|October 17, 2025
Phenotypic Switch From Atopic Dermatitis to Psoriasis During Dupilumab Therapy: A Real-Life Experience From a Tertiary Referral CenterAlessandra Chiei Gallo, Gianluca Tavoletti, Davide Termini, et al.
The Journal of Dermatology|August 17, 2022
Five cases of new-onset pemphigus following vaccinations against coronavirus disease 2019Alberto Corrá, Francesca Barei, Giovanni Genovese, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 28, 2024
Effectiveness of dupilumab in tralokinumab-resistant patients with atopic dermatitis: A real-world experience from two referral centresGianluca Tavoletti, Alessandra Chiei-Gallo, Luigi Gargiulo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 27, 2022
Clinical spectrum of human monkeypox: An Italian single-centre case seriesItalo F Aromolo, Carlo A Maronese, Gianluca Avallone, et al.
Journal of the American Academy of Dermatology|July 24, 2024
Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series studyElena Pezzolo, Alessandra Narcisi, Luigi Gargiulo, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|July 31, 2025
Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort StudyGianluca Avallone, Luca Valtellini, Gianluca Tavoletti, et al.
Journal of Clinical Medicine|January 23, 2024
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter AnalysisElena Pezzolo, Michela Ortoncelli, Silvia Mariel Ferrucci, et al.
Archives of Dermatological Research|May 23, 2025
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis)Luca Potestio, Cataldo Patruno, Alessandra Narcisi, et al.
Clinical and Experimental Dermatology|February 3, 2025
Efficacy and Drug Survival of Tralokinumab in Severe Atopic Dermatitis: An 18-Month Multicenter ExperienceFrancesca Barei, Paolo Calzari, Elena Pezzolo, et al.
Pageof 6